• ADHD

Daytrana Generic Name & Formulations

General Description

Methylphenidate 10mg, 15mg, 20mg, 30mg; delivered over 9hrs; transdermal patches.

Pharmacological Class

CNS stimulant.

How Supplied



Generic Availability


Daytrana Indications


Attention deficit hyperactivity disorder.

Daytrana Dosage and Administration


Not applicable.


<6yrs: not established. 6–17yrs: Initially apply one 10mg patch to hip 2hrs before desired effect, remove 9hrs after application; may remove earlier if shorter duration of effect or late day side effects appear. May titrate dose at 1-week intervals. Reevaluate periodically. Rotate application sites.

Daytrana Contraindications


Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family. During or within 14 days of MAOIs.

Daytrana Boxed Warnings

Boxed Warning

Drug dependence.

Daytrana Warnings/Precautions


History of drug dependence or alcoholism; monitor for abnormal behavior. Discontinue if contact sensitization is suspected; may develop systemic sensitization with other MPH formulations (see full labeling). Avoid exposing patch to direct external heat sources. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. History of vitiligo. Monitor for signs of skin depigmentation; discontinue if chemical leukoderma develops. Monitor growth, BP, HR, CBCs, differential, platelet counts. Pregnancy. Nursing mothers: monitor infants.

Daytrana Pharmacokinetics

See Literature

Daytrana Interactions


See Contraindications. Hypertensive crisis with MAOIs. May potentiate coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), tricyclics (eg, imipramine, clomipramine, desipramine), SSRIs; may need dose adjustments. May antagonize antihypertensive agents; monitor and adjust dose of antihypertensives as needed. Caution with pressor agents. Concomitant risperidone may increase risk of extrapyramidal symptoms; monitor.

Daytrana Adverse Reactions

Adverse Reactions

Application site reactions (eg, erythema), decreased appetite, insomnia, nausea, vomiting, weight loss, tics, affect lability, anorexia, dizziness, abdominal pain; priapism, hypertension, tachycardia, visual disturbances.

Daytrana Clinical Trials

See Literature

Daytrana Note

Not Applicable

Daytrana Patient Counseling

See Literature